Gilead Sciences invests $320m in Arcus Biosciences to accelerate cancer treatment innovations
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have announced a significant amendment to their collaboration agreement, accompanied by a substantial $320 ... Read More
Gilead Sciences discontinues Phase 3 ENHANCE Study on higher-risk MDS due to futility
Biopharmaceutical firm Gilead Sciences (Nasdaq: GILD) has announced the termination of its Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) due to a lack ... Read More
Gilead Sciences announces Veklury EU approval for COVID-19 treatment
Veklury EU approval : Gilead Sciences said that Veklury (remdesivir) has been given conditional marketing authorization from the European Commission as a treatment for SARS-CoV-2 ... Read More
Gilead Covid-19 drug candidate remdesivir delivers desired results in phase 3 trial
Remdesivir clinical trial results : Gilead Sciences said that the phase 3 SIMPLE trial, which has been evaluating the Covid-19 drug candidate remdesivir for the ... Read More
Gilead Sciences bags Epclusa FDA approval for hepatitis C in pediatric patients
Epclusa FDA approval : Gilead Sciences has secured an expanded approval for Epclusa (sofosbuvir 400mg/velpatasvir 100mg; sofosbuvir 200mg/velpatasvir 50 mg) from the US Food and ... Read More